| | Authors | (Publication year) title | Source period (year) | Country | Antidiabetic medications |
| | Chang et al. [15] | (2012)
National trends in antidiabetic treatment in Taiwan, 2000–2009 | 2000–2009 | Taiwan | Biguanides, SU, Meglitinides, TZDs, α-glucosidase, DPP-4, insulin | | Abdelmoneim et al. [20] | (2013)
Use patterns of antidiabetic regimens by patients with type 2 diabetes | 1998–2010 | Canada | Biguanides, SU, Meglitinides, TZDs, α-glucosidase, insulin | | Kohro et al. [17] | (2013)
Trends in antidiabetic prescription patterns in Japan from 2005 to 2011—impact of the introduction of dipeptidyl peptidase-4 inhibitors | 2005–2011 | Japan | Biguanides, SU, Meglitinides, TZDs, α-glucosidase, DPP-4, GLP-1, insulin | | Hsu et al. [21] | (2015)
Utilization of oral antidiabetic medications in Taiwan following strategies to promote access to medicines for chronic diseases in community pharmacies | 2001–2010 | Taiwan | Biguanides, SU, Meglitinides, TZDs, α-glucosidase, DPP-4, GLP-1 | | Rafaniello et al. [18] | (2015)
Trends in the prescription of antidiabetic medications from 2009 to 2012 in a general practice of Southern Italy: a population-based study | 2009–2012 | Italy | Biguanides, SU, Meglitinides, TZDs, α-glucosidase, DPP-4, GLP-1, insulin | | Ko et al. [19] | (2016)
Trends of antidiabetic drug use in adult Type 2 diabetes in Korea in 2002–2013: nationwide population-based cohort study | 2002–2013 | Korea | Biguanides, SU, Meglitinides, TZDs, α-glucosidase, DPP-4, insulin | | Ou et al. [16] | (2016)
Recent trends in the use of antidiabetic medications from 2008 to 2013: a nationwide population-based study from Taiwan | 2008–2013 | Taiwan | Biguanides, SU, Meglitinides, TZDs, α-glucosidase, DPP-4, GLP-1, insulin |
|
|
